s6y

Adaptimmune Therapeutics PLC

Ticker
ADAPY
CIK
1621227
Industry
Biological Products, (No Diagnostic Substances)
Formerly
Adaptimmune Ltd

Financials 41

  1. 10-Q Quarterly Report for period ending Jun 30, 2025
  2. 10-Q Quarterly Report for period ending Mar 31, 2025
  3. 10-K Annual Report for period ending Dec 31, 2024
  4. 10-Q Quarterly Report for period ending Sep 30, 2024
  5. 10-Q Quarterly Report for period ending Jun 30, 2024
  6. 10-Q Quarterly Report for period ending Mar 31, 2024
  7. 10-K Annual Report for period ending Dec 31, 2023
  8. 10-Q Quarterly Report for period ending Sep 30, 2023
  9. 10-Q Quarterly Report for period ending Jun 30, 2023
  10. 10-Q Quarterly Report for period ending Mar 31, 2023

All 41 financials filings

News 199

  1. 8-K Current report filing
  2. 8-K Current report filing
  3. 8-K Current report filing
  4. 8-K Current report filing
  5. 8-K Current report filing
  6. 8-K Current report filing
  7. 8-K Current report filing
  8. 8-K Current report filing
  9. 8-K Current report filing
  10. 8-K Current report filing

All 199 news filings

Ownership 405

  1. 3 Initial statement of beneficial ownership of securities
  2. 4 Statement of changes in beneficial ownership of securities
  3. 4 Statement of changes in beneficial ownership of securities
  4. 4 Statement of changes in beneficial ownership of securities
  5. 4 Statement of changes in beneficial ownership of securities
  6. 4 Statement of changes in beneficial ownership of securities
  7. 4 Statement of changes in beneficial ownership of securities
  8. 4 Statement of changes in beneficial ownership of securities
  9. 4 Statement of changes in beneficial ownership of securities
  10. 4 Statement of changes in beneficial ownership of securities

All 405 ownership filings

Prospectus 40

  1. RW Registration Withdrawal Request
  2. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  3. S-8 POS Post-effective amendment to a S-8 registration statement
  4. S-8 POS Post-effective amendment to a S-8 registration statement
  5. S-8 POS Post-effective amendment to a S-8 registration statement
  6. S-3 Registration statement for specified transactions by certain issuers
  7. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  8. S-8 POS Post-effective amendment to a S-8 registration statement
  9. S-8 POS Post-effective amendment to a S-8 registration statement
  10. 425 Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions

All 40 prospectus filings

Proxies 17

  1. DEF 14A Definitive proxy statements
  2. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  3. DEF 14A Definitive proxy statements
  4. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  5. DEF 14A Definitive proxy statements
  6. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  7. DEF 14A Definitive proxy statements
  8. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  9. DEF 14A Definitive proxy statements
  10. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition

All 17 proxies filings

Other 106

  1. SCHEDULE 13G
  2. EFFECT Notice of Effectiveness
  3. SCHEDULE 13G/A
  4. 15-12G Notice of termination of registration of a class of securities under Section 12(g)
  5. POS AM Post-effective amendment to a registration statement that is not immediately effective upon filing
  6. 25 Notification filed by issuer to voluntarily withdraw a class of securities from listing and registration on a national securities exchange
  7. 144 Filing for proposed sale of securities under Rule 144
  8. 144 Filing for proposed sale of securities under Rule 144
  9. SCHEDULE 13D/A
  10. SCHEDULE 13G/A

All 106 other filings